What is FDMT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.74B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for FDMT?

P/E (TTM) is n/a and 52-week range is $6.96 to $16.93 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s FDMT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for FDMT?

The company profile lists revenue (TTM) near $68M, net income (TTM) near $-13.33B, EPS (TTM) near $-2.76 when available from the market-data feed. Figures are informational and may lag live markets.

Where is 4D Molecular Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Emeryville, California, US, 52.3M shares outstanding, ISIN US35104E1001 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

4D Molecular Therapeutics Inc

$FDMT

Health Care · Biotechnology

IR Run Scenarios

$13.33

+4.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. The company is headquartered in Emeryville, California and currently employs 196 full-time employees. The company went IPO on 2020-12-11. The firm's lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. Its lead indication for 4D-150 is wet age-related macular degeneration, which is in Phase III development, and second indication is diabetic macular edema. The firm is developing 4D-710 for the treatment of a range of people with cystic fibrosis independent of their specific CFTR mutation. 4D-710 is an investigational genetic medicine candidate using the A101 vector for the treatment of cystic fibrosis lung disease. The firm's non-core programs include 4D-175, 4D-725, and 4D-310.

Employees

196

Website

4dmoleculartherapeutics.com/

IPO

2020-12-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)